Medicines VP Unloads $2,535,750 in Stock (MDCO)
Medicines (NASDAQ:MDCO) VP Paul Michael Antinori sold 73,500 shares of the stock on the open market in a transaction dated Friday, September 13th. The stock was sold at an average price of $34.50, for a total value of $2,535,750.00. Following the transaction, the vice president now directly owns 51,906 shares of the company’s stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on MDCO shares. Analysts at Zacks reiterated a “neutral” rating on shares of Medicines (NASDAQ:MDCO) in a research note to investors on Monday. They now have a $36.00 price target on the stock. Separately, analysts at Bank of America Corp. upgraded shares of Medicines (NASDAQ:MDCO) from a “neutral” rating to a “buy” rating in a research note to investors on Thursday, August 15th. They now have a $40.00 price target on the stock, up previously from $36.00. Finally, analysts at RBC Capital raised their price target on shares of Medicines (NASDAQ:MDCO) from $41.00 to $42.00 in a research note to investors on Tuesday, August 6th. They now have an “outperform” rating on the stock.
Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $35.50.
Medicines (NASDAQ:MDCO) traded down 0.09% during mid-day trading on Tuesday, hitting $33.76. The stock had a trading volume of 368,945 shares. Medicines has a 1-year low of $20.04 and a 1-year high of $37.40. The stock has a 50-day moving average of $31.75 and a 200-day moving average of $32.58. The company has a market cap of $1.875 billion and a P/E ratio of 52.39.
Medicines (NASDAQ:MDCO) last released its earnings data on Wednesday, July 24th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.17. The company had revenue of $172.00 million for the quarter, compared to the consensus estimate of $168.70 million. During the same quarter in the previous year, the company posted $0.46 earnings per share. The company’s revenue for the quarter was up 27.3% on a year-over-year basis. Analysts expect that Medicines will post $0.70 EPS for the current fiscal year.
The Medicines Company is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.